The National Health Authority (NHA) has released a consultation paper on Drug Registry. Envisioned under the ambitious Ayushman Bharat Digital Mission (ABDM), drug registry is intended to be a single, up-to-date, centralised repository of all the drugs across all systems of medicine that are approved and are available in the Indian market. The drug registry application is proposed to be designed using open-source technologies and will be interoperable. 

The consultation paper focuses only on drug registry within the National Digital Health Ecosystem and offers NHA’s current vision on the functionalities of the proposed drug registry, the process for its creation and potential benefits to various ecosystem stakeholders. Each section has specific open questions where feedback from stakeholders is sought. Comments from the public are invited to ensure that Drug Registry is designed and developed in a collaborative and consultative manner. 

Dr RS Sharma, CEO, National Health Authority, remarked, “I urge all stakeholders to go through the shared consultation papers and provide us with their valuable feedback.”

NHA will organise a public webinar on drug registry to explain the consultation paper on April 19, 2022, from 3 pm onwards.